Stakeholders urge FDA to retain interchangeability statements on biosimilar labeling
Regulatory NewsJoanne S. Eglovitch
Advertising, Promotion and LabelingBiologics/ biosimilars/ vaccinesBiotechnologyRegulatory Intelligence/PolicyRegulatory writing/documentationUnited States